0.78
前日終値:
$0.7463
開ける:
$0.735
24時間の取引高:
88,783
Relative Volume:
0.21
時価総額:
$6.30M
収益:
$2.35M
当期純損益:
$-2.56M
株価収益率:
-1.7407
EPS:
-0.4481
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.11%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-58.02%
1年 パフォーマンス:
-58.95%
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
IMRN
Immuron Limited Adr
|
0.78 | 6.03M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immuron Limited Adr (IMRN) 最新ニュース
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Detroit Free Press
Immuron Reports HY26 Results and Strategic Reset - GlobeNewswire Inc.
Immuron Reports HY26 Results and Strategic Reset - Sahm
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - progress-index.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron Reports Continued Sales Growth - Finviz
Does Immuron Limited (Common Stock) (ANWA) stock trade below intrinsic valueJuly 2025 Spike Watch & Smart Investment Allocation Insights - DonanımHaber
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - The Globe and Mail
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com Australia
Orla Mining Ltd (ORLA) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com India
Immuron Limited announces quotation of new securities on ASX - MSN
Check Out IHS Holding Ltd (IHS)’s Trade Data Rather Than the Analysts’ Views - setenews.com
You might want to take a look at Embecta Corp (EMBC) now - setenews.com
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
ANWA Forecast — Price Target — Prediction for 2026 - TradingView — Track All Markets
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - FinancialContent
Why Immuron Limited (ANW) stock gets analyst attentionJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
IMRN Stock Price and Chart — NASDAQ:IMRN - TradingView
How Immuron Limited Depositary Receipt stock benefits from global expansion2025 Macro Impact & AI Driven Price Forecasts - Fundação Cultural do Pará
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Holdings of Immuron Limited ADR (IMRN) are aligned with the stars - Setenews
Immuron Limited Receives FDA Approval for IMM-529 Investigational New Drug Application for Clostridioides difficile Infection Treatment - Quiver Quantitative
Immuron IMM-529 IND approved by FDA - GlobeNewswire
Immuron CEO to Present at AusBiotech Invest 2025 Conference - MSN
Immuron Announces Clinical Trial Update - Sahm
Immuron Ltd (IMC:ASX) - smallcaps.com.au
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Ltd. (ADR) (US45254U1016.SG) Stock Price, News, Quote & History - Yahoo
Immuron Q1 FY26 YoY growth - Finviz
Immuron Limited Announces 2025 Annual General Meeting - MSN
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
Immuron Limited Adr (IMRN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):